Table 4.

3-Hydroxykynurenine (3-OHKY) and neurological symptoms predict clinical symptoms for first-episode schizophrenia patients

	R	Adj. R2	F ratio	d.f.	p≤	β	S.E. β	t test	p≤	95% CI
(a) Baseline metabolite and neurological factors predict baseline clinical symptomsa
(1) BPRS Total symptoms	0.64	0.38	14.17	1, 20	0.001b
3-OHKY						−4.418	1.174	−3.76	0.001b	−6.866 to −1.97
(2) BPRS Psychosis symptoms	0.68	0.44	17.66	1, 20	0.001b
Neurological symptoms, Total						5.849	1.392	4.20	0.001b	2.946 to 8.753
(3) BPRS Mood symptoms	0.76	0.53	12.78	2, 19	0.001b
3-OHKY						−3.319	0.746	−4.45	0.001b	−4.880 to −1.758
Neurological symptoms, Total						−7.318	2.191	−3.34	0.003b	−11.904 to −2.733
(b) Baseline metabolite predicts clinical change at 4 wk
(1) BPRS Total symptom change	0.66	0.41	15.68	1, 20	0.001b
3-OHKY						−0.733	0.185	−3.96	0.001b	−1.120 to −0.347
(2) BPRS Psychosis symptom change	0.62	0.35	12.58	1, 20	0.002b
3-OHKY						−0.252	0.071	−3.55	0.002b	−0.401 to −0.104
(3) BPRS Mood symptom change	0.64	0.38	14.15	1, 20	0.001b
3-OHKY						−0.502	0.134	−3.76	0.001b	−0.781 to −0.224

R, Multiple correlation coefficient; F ratio, test of significance of R; d.f., degrees of freedom; β, regression coefficient or slope ; S.E., standard error ; CI, confidence interval for regression coefficient; BPRS, Brief Psychiatric Rating Scale.

^aPredictors : 3-hydroxykynurenine and neurological symptoms – Total.

^bBonferroni correction of standard α≤0.05≤0.0083 ; p≤0.10≤0.016.